Overview of Research and Development for Anticancer Drugs — Oak Academic Publishing
Research ArticleOpen AccessGoogle Scholar indexed
Overview of Research and Development for Anticancer Drugs
Shanghai Jiao Tong University School of Medicine, Shanghai, China
,
Lab of Microbial and Biochemical Pharmaceutical, School of Pharmacy, Shanghai Jiao Tong University, Shanghai, China
,
Engineering Research Center of Cell and Therapeutic Antibody, Ministry of Education, School of Pharmacy, Shanghai Jiao Tong University, Shanghai, China
1 Shanghai Jiao Tong University School of Medicine, Shanghai, China
2 Lab of Microbial and Biochemical Pharmaceutical, School of Pharmacy, Shanghai Jiao Tong University, Shanghai, China
3 Engineering Research Center of Cell and Therapeutic Antibody, Ministry of Education, School of Pharmacy, Shanghai Jiao Tong University, Shanghai, China
Anticancer drugs research and development ha ve been the largest market area in the pharmaceutical industry in terms of the number of project, clinical trials and spending. In the last 10 - 30 years, targeting therapy for cancers has been developed and achieved enormous clinical effectiveness by transforming some previously deadly malignancies into chronically manageable conditions, but cure problem still remains. This mini review outlined the current status of anticancer drugs development and hinted the opinions of how to further increase the accuracy and efficacy of discovery for cancer treatment.
KeywordsAnticancer DrugsResearch and DevelopmentTarget TherapyPhenotype TargetingAnti-Tumor Immunity
Mehta, K., Gandhi, V., Pathak, S., Aggarwal, B.B. and Grover, R.K. (2014) Multi-Targeted Approach to Cancer Treatment: An International Translational Cancer Research Symposium. Anticancer Research, 34, 6791-6795.
Moffat, J.G., Rudolph, J. and Bailey, D. (2014) Phenotypic Screening in Cancer Drug Discovery—Past, Present and Future. Nature Reviews Drug Discovery, 13, 588-602. http://dx.doi.org/10.1038/nrd4366
Adams, D.J. (2012) The Valley of Death in Anticancer Drug Development: A Reassessment. Trends in Pharmacological Sciences, 33, 173-180. http://dx.doi.org/10.1016/j.tips.2012.02.001
Bailón-Moscoso, N., Romero-Benavides, J.C. and Ostrosky-Wegman, P. (2014) Development of Anticancer Drugs Based on the Hallmarks of Tumor Cells. Tumor Biology, 35, 3981-3995. http://dx.doi.org/10.1007/s13277-014-1649-y
Widmer, N., Bardin, C., Chatelut, E., Paci, A., Beijnen, J., Levêque, D., et al. (2014) Review of Therapeutic Drug Monitoring of Anticancer Drugs Part Two—Targeted Therapies. European Journal of Cancer, 50, 2020-2036. http://dx.doi.org/10.1016/j.ejca.2014.04.015
Lim, S.H. and Levy, R. (2014) Translational Medicine in Action: Anti-CD20 Therapy in Lymphoma. The Journal of Immunology, 193, 1519-1524. http://dx.doi.org/10.4049/jimmunol.1490027
Brown, C. (2016) Targeted Therapy: An Elusive Cancer Target. Nature, 537, S106-S108. http://dx.doi.org/10.1038/537s106a
Zhou, L., Xu, N., Sun, Y. and Liu, X.M. (2014) Targeted Biopharmaceuticals for Cancer Treatment. Cancer Letters, 352, 145-151. http://dx.doi.org/10.1016/j.canlet.2014.06.020
Herviou, P., Thivat, E., Richard, D., Roche, L., Dohou, J., Pouget, M., Eschalier, A., Durando, X. and Authier, N. (2016) Therapeutic Drug Monitoring and Tyrosine Kinase Inhibitors. Oncology Letters, 12, 1223-1232.
Obenauf, A.C., Zou, Y., Ji, A.L., Vanharanta, S.N, Shu, W., Shi, H., et al. (2015) Therapy-Induced Tumour Secretomes Promote Resistance and Tumour Progressio. Nature, 520, 368-372. http://dx.doi.org/10.1038/nature14336
Juric, D., Castel, P., Griffith, M., Griffith, O.L., Won, H.H. and Ellis, H. (2015) Convergent Loss of PTEN Leads to Clinical Resistance to a PI(3)Kα Inhibitor. Nature, 518, 240-244. http://dx.doi.org/10.1038/nature13948
Lieu, C.H., Tan, A.C., Leong, S., Diamond, J.R. and Eckhardt, S.G. (2013) From Bench to Bedside: Lessons Learned in Translating Preclinical Studies in Cancer Drug Development. Journal of the National Cancer Institute, 105, 1441-1456. http://dx.doi.org/10.1093/jnci/djt209
Ryall, K.A. and Tan, A.C. (2015) Systems Biology Approaches for Advancing the Discovery Of Effective Drug Combinations. Journal of Cheminformatics, 7, 7. http://dx.doi.org/10.1186/s13321-015-0055-9
Martz, C.A., Ottina, K.A., Singleton, K.R., Jasper, J.S., Wardell, S.E., Peraza-Penton, A., et al. (2014) Systematic Identification of Signaling Pathways with Potential to Confer Anticancer Drug Resistance. Science Signaling, 7, ra121. http://dx.doi.org/10.1126/scisignal.aaa1877
Crystal, A.S., Shaw, A.T., Sequist, L.V., Friboulet, L., Niederst, M.J., Lockerman, E.L., et al. (2014) Patient-Derived Models of Acquired Resistance Can Identify Effective Drug Combinations for Cancer. Science, 346, 1480-1486. http://dx.doi.org/10.1126/science.1254721
Frangione, M.L., Lockhart, J.H., Morton, D.T., Pava, L.M. and Blanck, G. (2015) Anticipating Designer Drug-Resistant Cancer Cells. Drug Discovery Today, 20, 790-793. http://dx.doi.org/10.1016/j.drudis.2015.02.005
Tong, L., Chuang, C.C., Wu, S. and Zuo, L. (2015) Reactive Oxygen Species in Redox Cancer Therapy. Cancer Letters, 367, 18-25. http://dx.doi.org/10.1016/j.canlet.2015.07.008
Yang, W., Zou, L., Huang, C. and Lei, Y. (2014) Redox Regulation of Cancer Metastasis: Molecular Signaling and Therapeutic Opportunities. Drug Development Research, 75, 331-341. http://dx.doi.org/10.1002/ddr.21216
Gad, H., Koolmeister, T., Jemth, A.S., Eshtad, S., Jacques, S.A. and Strom, C.E. (2014) MTH1 Inhibition Eradicates Cancer by Preventing Sanitation of the dNTP Pool. Nature, 508, 215-222 http://dx.doi.org/10.1038/nature13181
Kawagishi, H. and Finkel, T. (2014) Unraveling the Truth about Antioxidants: ROS and Disease: Finding the Right Balance. Nature Medicine, 20, 711-713. http://dx.doi.org/10.1038/nm.3625
Sabharwal, S.S. and Schumacker, P.T. (2014) Mitochondrial ROS in Cancer: Initiators, Amplifiers or an Achilles’ Heel? Nature Reviews Cancer, 14, 709-721. http://dx.doi.org/10.1038/nrc3803
Ristow, M. (2014) Unraveling the Truth about Antioxidants: Mitohormesis Explains ROS-Induced Health Benefits. Nature Medicine, 20, 709-711. http://dx.doi.org/10.1038/nm.3624
Ibanez, I.L., Notcovich, C., Catalano, P.N., Bellino, M.G. and Durán, H. (2015) The Redox-Active Nanomaterial Toolbox for Cancer Therapy. Cancer Letters, 359, 9-19. http://dx.doi.org/10.1016/j.canlet.2015.01.013
Lu, M., Lawrence, D.A., Marsters, S., Acosta-Alvear, D., Kimmig, P., Mendez, A.S., et al. (2014) Opposing Unfolded-Protein-Response Signals Converge on Death Receptor 5 to Control Apoptosis. Science, 345, 98-101. http://dx.doi.org/10.1126/science.1254312
Wang, M. and Kaufman, R.J. (2014) The Impact of the Endoplasmic Reticulum Protein-Folding Environment on Cancer Development. Nature Review Cancer, 14, 581-597. http://dx.doi.org/10.1038/nrc3800
Hiramatsu, N., Chiang, W.C., Kurt, T.D., Sigurdson, C.J. and Lin, J.H. (2015) Multiple Mechanisms of Unfolded Protein Response-Induced Cell Death. American Journal of Pathology, 185, 1800-1808. http://dx.doi.org/10.1016/j.ajpath.2015.03.009
Maas, N.L. and Diehl, J.A. (2015) Molecular Pathways: The PERKs and Pitfalls of Targeting the Unfolded Protein Response in Cancer. Clinical Cancer Research, 21, 675-679. http://dx.doi.org/10.1158/1078-0432.CCR-13-3239
Lee, A.S. (2014) Glucose-Regulated Proteins in Cancer: Molecular Mechanisms and Therapeutic Potential. Nature Review Cancer, 14, 263-276. http://dx.doi.org/10.1038/nrc3701
Tan, J.S., Ong, K.K.C. and Rhodes, A. (2016) The Role of Heat Shock Proteins and Glucose Regulated Proteins in Cancer. Malaysian Journal of Pathology, 38, 75-82.
Brüning, A. and Jückstock, J. (2015) Misfolded Proteins: From Little Villains to Little Helpers in the Fight against Cancer. Frontiers in Oncology, 5, 47.
Solárová, Z., Mojzis, J. and Solár, P. (2015) Hsp90 Inhibitor as a Sensitizer of Cancer Cells to Different Therapies. International Journal of Oncology, 46, 907-926.
Kukita, K., Tamura, Y., Tanaka, T., Kajiwara, T., Kutomi, G., Saito, K., et al. (2015) Cancer-Associated Oxidase ERO1-α Regulates the Expression of MHC Class I Molecule via Oxidative Folding. The Journal of Immunology, 194, 4988-4996. http://dx.doi.org/10.4049/jimmunol.1303228
Tanaka, T., Kajiwara, T., Torigoe, T., Okamoto, Y., Sato, N. and Tamura, Y. (2015) Cancer-Associated Oxidoreductase ERO1-α Drives the Production of Tumor-Promoting Myeloid-Derived Suppressor Cells via Oxidative Protein Folding. The Journal of Immunology, 194, 2004-2010. http://dx.doi.org/10.4049/jimmunol.1402538
Delaunay-Moisan, A. and Appenzeller-Herzog, C. (2015) The Antioxidant Machinery of the Endoplasmic Reticulum: Protection and Signaling. Free Radical Biology & Medicine, 83, 341-351. http://dx.doi.org/10.1016/j.freeradbiomed.2015.02.019
Clarke, H.J., Chambers, J.E., Liniker, E. and Marciniak, S.J. (2014) Endoplasmic Reticulum Stress in Malignancy. Cancer Cell, 25, 563-573. http://dx.doi.org/10.1016/j.ccr.2014.03.015
Hu, Z.Y., Xiao, L., Bode, A.M., Dong, Z. and Cao, Y. (2014) Glycolytic Genes in Cancer Cells Are More than Glucose Metabolic Regulators. Journal of Molecular Medicine, 92, 837-845. http://dx.doi.org/10.1007/s00109-014-1174-x
Michels, J., Obrist, F., Castedo, M., Vitale, I. and Kroemer, G. (2014) PARP and Other Prospective Targets for Poisoning Cancer Cell Metabolism. Biochemical Pharmacology, 92, 164-171. http://dx.doi.org/10.1016/j.bcp.2014.08.026
Augoff, K., Hryniewicz-Jankowska, A. and Tabola, R. (2015) Lactate Dehydrogenase 5: An Old Friend and a New Hope in the War on Cancer. Cancer Letters, 358, 1-7. http://dx.doi.org/10.1016/j.canlet.2014.12.035
Fiume, L., Manerba, M., Vettraino, M. and Di Stefano, G. (2014) Inhibition of Lactate Dehydrogenase Activity as an Approach to Cancer Therapy. Future Medicinal Chemistry, 6, 429-445. http://dx.doi.org/10.4155/fmc.13.206
Yélamos, J., Galindo, M., Navarro, J., Albanell, J., Rovira, A., Rojo, F. and Oliver, J. (2015) Enhancing Tumor-Targeting Monoclonal Antibodies Therapy by PARP Inhibitors. Oncoimmunology, 5, e1065370. http://dx.doi.org/10.1080/2162402X.2015.1065370
Rodríguez-Enríquez, S., Gallardo-Pérez, J.C., Hernández-Reséndiz, I., Marín-Hernández, A., Pacheco-Velázquez, S.C., López-Ramírez, S.Y., et al. (2014) Canonical and New Generation Anticancer Drugs Also Target Energy Metabolism. Archives of Toxicology, 88, 1327-1350. http://dx.doi.org/10.1007/s00204-014-1246-2
Bhat, T.A., Kumar, S., Chaudhary, A.K., Yadav, N. and Chandra, D. (2015) Restoration of Mitochondria Function as a Target for Cancer Therapy. Drug Discovery Today, 20, 635-643. http://dx.doi.org/10.1016/j.drudis.2015.03.001
Ji, D., Beharry, A.A., Ford, J.M. and Kool, E.T. (2016) A Chimeric ATP-Linked Nucleotide Enables Luminescence Signaling of Damage Surveillance by MTH1, a Cancer Target. Journal of the American Chemical Society, 138, 9005-9008. http://dx.doi.org/10.1021/jacs.6b02895
Huber, K.V., Salah, E., Radic, B., Gridling, M., Elkins, J.M., Stukalov, A., et al. (2014) Stereospecific Targeting of MTH1 by (S)-Crizotinib as an Anticancer Strategy. Nature, 508, 222-227. http://dx.doi.org/10.1038/nature13194
DuPage, M., Mazumdar, C., Schmidt, L.M., Cheung, A.F. and Jacks, T. (2012) Expression of tumour-Specific Antigens Underlies Cancer Immunoediting. Nature, 482, 405-409. http://dx.doi.org/10.1038/nature10803
Teng, M.W., Galon, J., Fridman, W.H. and Smyth, M.J. (2015) From Mice to Humans: Developments in Cancer Immunoediting. Journal of Clinical Investigation, 125, 3338-3346. http://dx.doi.org/10.1172/JCI80004
Kareva, I. and Berezovskaya, F. (2015) Cancer Immunoediting: A Process Driven by Metabolic Competition as a Predator-Prey-Shared Resource Type Model. Journal of Theoretical Biology, 380, 463-472. http://dx.doi.org/10.1016/j.jtbi.2015.06.007
Makkouk, A. and Weiner, G.J. (2015) Cancer Immunotherapy and Breaking Immune Tolerance: New Approaches to an Old Challenge. Cancer Research, 75, 5-10. http://dx.doi.org/10.1158/0008-5472.CAN-14-2538
Aranda, F., Vacchelli, E., Obrist, F., Eggermont, A., Galon, J., Sautès-Fridman, C., et al. (2014) Trial Watch: Toll-Like Receptor Agonists in Oncological Indications. Oncoimmunology, 3, e29179. http://dx.doi.org/10.4161/onci.29179
Herbst, R.S., Soria, J.C., Kowanetz, M., Fine, G.D., Hamid, O., Gordon, M.S., et al. (2014) Predictive Correlates of Response to the Anti-PD-L1 Antibody MPDL3280A in Cancer Patients. Nature, 515, 563-567. http://dx.doi.org/10.1038/nature14011
Aranda, F., Vacchelli, E., Eggermont, A., Galon, J., Sautès-Fridman, C., Tartour, E., et al. (2013) Trial Watch: Peptide Vaccines in Cancer Therapy. Oncoimmunology, 2, e26621. http://dx.doi.org/10.4161/onci.26621
Pauken, K.E. and Wherry, E.J. (2014) TIGIT and CD226: Tipping the Balance between Costimulatory and Coinhibitory Molecules to Augment the Cancer Immunotherapy Toolkit. Cancer Cell, 26, 785-787. http://dx.doi.org/10.1016/j.ccell.2014.11.016
Vacchelli, E., Aranda, F., Eggermont, A., Galon, J., Sautès-Fridman, C., Zitvogel, L., et al. (2014) Trial Watch: Tumor-Targeting Monoclonal Antibodies in Cancer Therapy. Oncoimmunology, 3, e27048. http://dx.doi.org/10.4161/onci.27048
Zheng, Y., Dou, Y., Duan, L., Cong, C., Gao, A., Lai, Q., et al. (2015) Using Chemo-Drugs or Irradiation to Break Immune Tolerance and Facilitate Immunotherapy in Solid Cancer. Cellular Immunology, 294, 54-59. http://dx.doi.org/10.1016/j.cellimm.2015.02.003
Gomez-Roca, C. and Delord, J.P. (2014) Emerging New Anticancer Therapies in 2013. Current Opinion in Oncology, 26, 357-362. http://dx.doi.org/10.1097/CCO.0000000000000081
Naidoo, J., Page, D.B., Li, B.T., Connell, L.C., Schindler, K., Lacouture, M.E., Postow, M.A. and Wolchok, J.D. (2015) Toxicities of the Anti-PD-1 and Anti-PD-L1 Immune Checkpoint Antibodies. Annals of Oncology, 27, 1362. http://dx.doi.org/10.1093/annonc/mdw141
Hoffman, R.M. and Zhao, M. (2014) Methods for the Development of Tumor-Targeting Bacteria. Expert Opinion on Drug Discovery, 9, 741-750. http://dx.doi.org/10.1517/17460441.2014.916270
Dhillon, S. (2015) Dinutuximab: First Global Approval. Drugs, 75, 923-927. http://dx.doi.org/10.1007/s40265-015-0399-5
Sharma, P. and Allison, J.P. (2015) The Future of Immune Checkpoint Therapy. Science, 348, 56-61. http://dx.doi.org/10.1126/science.aaa8172
Shahabi, V., Postow, M.A., Tuck, D. and Wolchok, J.D. (2015) Immune-Priming of the Tumor Microenvironment by Radiotherapy: Rationale for Combination with Immunotherapy to Improve Anticancer Efficacy. American Journal of Clinical Oncology, 38, 90-97. http://dx.doi.org/10.1097/COC.0b013e3182868ec8
André, N., Carré, M. and Pasquier, E. (2014) Metronomics: Towards Personalized Chemotherapy? Nature Reviews Clinical Oncology, 11, 413-431. http://dx.doi.org/10.1038/nrclinonc.2014.89
Demaria, S., Pilones, K.A., Vanpouille-Box, C., Golden, E.B. and Formenti, S.C. (2014) The Optimal Partnership of Radiation and Immunotherapy: From Preclinical Studies to Clinical Translation. Radiation Research, 182, 170-181. http://dx.doi.org/10.1667/RR13500.1
Esposito, A., Criscitiello, C. and Curigliano, G. (2015) Immune Checkpoint Inhibitors with Radiotherapy and Locoregional Treatment: Synergism and Potential Clinical Implication. Current Opinion in Oncology, 27, 445-451. http://dx.doi.org/10.1097/CCO.0000000000000225
Regal, J.F., Dornfeld, K.J. and Fleming, S.D. (2016) Radiotherapy: Killing with Complement. Annals of Translational Medicine, 4, 94. http://dx.doi.org/10.21037/atm.2015.12.46